Amgen (AMGN) EPS (Weighted Average and Diluted) (2009 - 2026)

Amgen's EPS (Weighted Average and Diluted) history runs 18 years deep, the most recent figure standing at $3.34 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 4.37% year-over-year to $3.34; the TTM figure through Mar 2026 stood at $14.38 (up 31.2% YoY), while the FY2025 annual figure was $14.23, up 88.23% from the prior year.
• EPS (Weighted Average and Diluted) was $3.34 for Q1 2026 at Amgen, up from $2.46 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $5.93 in Q3 2025 to a low of -$0.21 in Q1 2024.
• Historically, EPS (Weighted Average and Diluted) has averaged $2.93 across 5 years, with a median of $2.68 in 2022.
• The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) tumbled 103.98% in 2024, then soared 1623.81% in 2025.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.0 in 2022, then sank by 52.33% to $1.43 in 2023, then retreated by 18.88% to $1.16 in 2024, then surged by 112.07% to $2.46 in 2025, then surged by 35.77% to $3.34 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $3.34 (Q1 2026), $2.46 (Q4 2025), and $5.93 (Q3 2025), per Business Quant data.